Press Releases

 2010

Date Title
01/05 Bioject Establishes Strategic Alliance with MPI Research

 

 

  2009

Date Title
12/21 Bioject Closes Previously Announced Equity Financing
11/05 Bioject Reports Third Quarter 2009 Results (Audio)
11/04 Bioject Reports Third Quarter 2009 Results
10/30 Bioject to Report Third Quarter 2009 Financial Results
08/06 Bioject Reports Second-Quarter 2009 Financial Results (Audio)
08/05 Bioject Reports Second-Quarter 2009 Financial Results
05/06 Bioject Reports First Quarter 2009 Financial Results
05/05 Bioject Signs CRADA with US Navy to Study a Malaria Vaccine
04/14 Bioject Meets Milestone for Merial Limited
04/06 Bioject Announces FDA Market Clearance for the Zetajet™ Needle-Free Injection Therapy System
03/27 Fourth Quarter and Year-End 2008 Financial Results (Audio)
03/25 Bioject Reports December 31, 2008 Results
02/24 Bioject Enters into a Collaborative Research Agreement with IAVI for the Delivery of an HIV Vaccine Candidate
02/10 Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.

 

 | 2008

Date Title
12/09 SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
11/10 Bioject Reports Third-Quarter 2008 Results
11/06 U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
08/19 Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
08/06 Bioject Reports Second-Quarter 2008 Financial Results
07/22 Bioject to Be Transferred to the over-the-Counter Bulletin Board
07/17 Biojector®2000 Data Presented in Vical’s Pandemic Influenza DNA Vaccine Human Trial
06/23 Bioject Announces Long-Term Agreement With Merial Limited
06/05

Bioject and ImmunoVaccine Technologies Announce Research Collaboration
05/27 Biojector®2000 Technology Put to the Test in CDC Flu Vaccine Study
05/23 Bioject Receives Nasdaq Staff Detemination
05/07 First Quarter 2008 Earnings Release
03/17 Bioject Reports December 31, 2007 Results and Initiates New Strategy